InvestorsHub Logo
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

Re: investingdog post# 153513

Saturday, 12/28/2013 11:22:28 PM

Saturday, December 28, 2013 11:22:28 PM

Post# of 345849

A lot of irrational exuberance here. Big pharma is not affraid of PPHM. The lack of partnership is the proof of that, if they were affraid they would have tripped over each other running to Peregrine to partner first and keep the others out.



I disagree. The lack of partnership is meaningless at this point. Lets say a small biotech actually does have something of normal value for a Big Pharma...those Big Pharma type deals are made thru the pressure coming crashing down upon the small biotech!

Peregrine Pharmaceuticals does not have something of "NORMAL" value, Peregrine has something of "HISTORIC" value:
--------------------------------------------------------------

The discovery of flipped-PS on every cancer cell that kills millions of lives each year.

The discovery of "Bavituximab" that targets "ALL" flipped-PS in millions upon millions of human beings is exactly what allows for an immune response to fight back cancer.

The discoveries were those of Dr. Philip Thorpe.

Lets just say Peregrine will be advancing Bavituximab in a way where multiple Big Pharmas will be at risk of going under.... the pressure is not on Peregrine, but by certain BP's.

Fargo may have kicked Peregrine into a gear not yet seen by Big Pharma.... and its forcing change

When was the last time K&L Gates was retained by a small biotech with Peregrines current market cap and filed for a $100 Million Preferred share S-3 filing.... ? NEVER

The pressure is on Big Pharma.... not Peregrine.






"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline."
-- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent CDMO News